Sonnet BioTherapeutics Holdings

SONN62

High Growth

$6.11arrow_drop_up25.19%$1.28

High Growth

SONN62

$6.11

arrow_drop_up25.19%$1.28

High Growth

Performance History

Key Stats
Open	$5.29
Prev. Close	$5.08
EPS	-0.96
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$3.14M
PE Ratio	-

	LOW	HIGH
Day Range	5.11	5.81
52 Week Range	4.96	20.88

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.96

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Sonnet BioTherapeutics Holdings (SONN)

Sonnet BioTherapeutics Holdings Inc (SONN) operates as a clinical-stage biopharmaceutical company, focusing on the development of innovative and targeted biologic drugs for the treatment of various diseases. The company utilizes its unique platform, called FHAB™ (Fully Human Albumin Binding), to engineer and develop next-generation therapeutics. By leveraging the albumin-binding technology, Sonnet aims to improve drug efficacy, enhance drug delivery, and minimize toxicities associated with traditional treatments.

SONN stock has shown significant volatility in its price history. Over the past year, the stock has experienced fluctuations between a 52-week high of $12.25 and a 52-week low of $1.20. This wide range demonstrates the potential for significant gains or losses for investors in the company. It is important for investors to consider the risk associated with investing in a clinical-stage biopharmaceutical company, as the success of drug development and clinical trials can have a substantial impact on the stock price.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Pankaj Mohan Ph.D.
Headquarters: Princeton
Employees: 12
Exchange: NASDAQ

add Sonnet BioTherapeutics Holdings to watchlist

Keep an eye on Sonnet BioTherapeutics Holdings

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Sonnet BioTherapeutics Holdings 's (SONN) price per share?

The current price per share for Sonnet BioTherapeutics Holdings (SONN) is $6.11. The stock has seen a price change of $1.28 recently, indicating a 25.2% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Sonnet BioTherapeutics Holdings (SONN)?

For Sonnet BioTherapeutics Holdings (SONN), the 52-week high is $20.88, which is 241.73% from the current price. The 52-week low is $4.96, the current price is 23.19% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Sonnet BioTherapeutics Holdings (SONN) a growth stock?

Sonnet BioTherapeutics Holdings (SONN) has shown an average price growth of -1.93% over the past three years. It has received a score of 85 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Sonnet BioTherapeutics Holdings as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Sonnet BioTherapeutics Holdings (SONN) stock price performance year to date (YTD)?

As of the latest data, Sonnet BioTherapeutics Holdings (SONN) has a year-to-date price change of -56.61%. Over the past month, the stock has experienced a price change of -22.46%. Over the last three months, the change has been -15.14%. Over the past six months, the figure is -55.07%.

help

Is Sonnet BioTherapeutics Holdings (SONN) a profitable company?

Sonnet BioTherapeutics Holdings (SONN) has a net income of -$18.83M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 48.75% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -21.97K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $72.06K. Operating income is noted at -$18.79M. Furthermore, the EBITDA is -$12.26M.

help

What is the market capitalization of Sonnet BioTherapeutics Holdings (SONN)?

Sonnet BioTherapeutics Holdings (SONN) has a market capitalization of $3.15M. The average daily trading volume is 5.7, indicating the stock's liquidity and investor engagement.